Exelixis, an oncology company based in Alameda, California, focuses on developing treatments for difficult-to-treat cancers, with four marketed products including cabozantinib for various cancers. Founded in 2000, it employs 1,310 people.
Tomas J Heyman sold 4,544 shares of EXEL on 21 May at $44.29 per share, worth a total of $201K. They now own 32,470 EXEL shares, or a 12% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
